Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)

NCT04623099 is registered in ClinicalTrials.gov with University of Cincinnati as lead sponsor.

NCT NCT04623099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04623099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
Lead sponsor
University of Cincinnati
Phase
Phase 4
Overall status
Recruiting
Start date
March 8, 2021
Completion date
December 1, 2026
Enrollment
132 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety